Evaluating the evidence for over-the-counter alternatives for relief of hot flashes in menopausal women

Journal of the American Pharmacists Association

Volumn 50, Issue 5, 2010, Pages

  Kelley, Kristi W ^a   Carroll, Dana G ^a  

^a AUBURN UNIVERSITY   (United States)

Author keywords

Hot flashes; Menopause; Nonprescription medications; OTC products; Pharmacotherapy

Indexed keywords

NON PRESCRIPTION DRUG;

ALTERNATIVE MEDICINE; CLINICAL TRIAL (TOPIC); DRUG INTERACTION; FEMALE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; MENOPAUSE; PATHOPHYSIOLOGY; PHYTOTHERAPY; REVIEW; RISK REDUCTION; TIME;

CLINICAL TRIALS AS TOPIC; COMPLEMENTARY THERAPIES; DRUG INTERACTIONS; FEMALE; HORMONE REPLACEMENT THERAPY; HOT FLASHES; HUMANS; MENOPAUSE; NONPRESCRIPTION DRUGS; PHYTOTHERAPY; RISK REDUCTION BEHAVIOR; TIME FACTORS;

EID: 79952779679     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/JAPhA.2010.09243     Document Type: Review

References (67)

1. Morelli V, Naquin C. Alternative therapies for traditional disease states: menopause. Am Fam Physician. 2002;66:129-34.
2. North American Menopause Society. Section C: common clinical issues during perimenopause and beyond. In: Menopause practice: a clinician's guide. 3rd ed. Mayfield Heights, OH: North American Menopause Society; 2007:29-102.
3. Sicatt BL, Brokaw DK. Nonhormonal alternatives for the treatment of hot flashes. Pharmacotherapy. 2004;24:79-93.
4. Shanafelt TD, Barton DL, Adjei AA, Loprinzi CL. Pathophysiology and treatment of hot flashes. Mayo Clin Proc. 2002;77:1207-18.
5. Rossouw JE, Anderson GL, Prentice RL, et al. Writing group for the Women's Health Initiative Investigators: risks and benefits of estrogen plus progestin in healthy menopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-33.
6. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy. JAMA. 2004;291:47-53.
7. Hulley S, Furberg C, Barrett-Conner E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow up (HERS II). JAMA. 2002;288:58-66.
8. Grady D, Herrington D, Bittner V, Blumenthal R, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow up (HERS II). JAMA. 2002;288:49-57.
9. American College of Obstetricians and Gynecologists. Vasomotor symptoms. Obstet Gynecol. 2004;4(suppl):106-17S.
10. North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: position statement of the North American Menopause Society. Menopause. 2004;11:11-33.
11. North American Menopause Society. Position statement: estrogen and progestogen use in postmenopausal women. Menopause. 2008;15:584-603.
12. Kronenberg F, Fugh-Berman A. Complimentary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med. 2002;137:805-13.
13. Loprinzi CL, Sloan JA, Perez EA. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol. 2002;20:1578-83.
14. Wiklund I, Holst J, Karlberg J. A new methodological approach to the evaluation of quality of life in postmenopausal women. Maturitas. 1992;14:211-24.
15. Greene JG. Constructing a standard climacteric scale. Maturitas. 1998;29:25-31.
16. Perez D, Loprinzi CL, Barton DL, et al. Pilot evaluation of mirtazapine for the treatment of hot flashes. J Support Oncol. 2004;2:50-6.
17. North American Menopause Society. Section J: counseling issues. In: Menopause practice: a clinician's guide. 3rd ed. Mayfield Heights, OH: North American Menopause Society; 2007:277-98.
18. Germaine LM, Freedman RR. Behavioral treatment of menopausal hot flashes: evaluation by objective measures. J Consult Clin Psychol. 1984;52:1072-9.
19. Lethaby A, Majoribanks L, Kronenberg F, et al. Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Syst Rev. 2007;CD001395.
20. Soy. Natural medicines comprehensive database [database online]. Stockton, CA: Therapeutic Research Center. Updated July 1, 2010.
21. Campagnoli C, Abba C, Ambroggio S, et al. Polyunsaturated fatty acids (PUFA) might reduce hot flushes: an indication from two controlled trials on soy isoflavones alone and with PUFA supplement. Maturitas. 2005;51:127-34.
22. Duffy R, Wiseman H, File SE. Improved congnitive function in postmenopausal women after 12 weeks of consumption of soy extract containing isoflavones. Pharmacol Biochem Behav. 2003;75:721-9.
23. Penotti M, Fabio E, Modena AB, et al. Effects of soy-derived isoflavones on hot flushes, endometrial thickness and the pulsatility index of the uterine and cerebral arteries. Fertil Steril. 2003;79:1112-7.
24. Faure ED, Chantre P, Mares P. Effects of a standardized soy extract on hot flushes: a multicentre, double blind, randomized placebo-controlled study. Menopause. 2002;9:329-34.
25. Han KK, Soares JM, Haidar MA, et al. Benefits of soy isoflavone therapeutic regimen on menopausal symptoms. Obstet Gyncol. 2002;99:389-94.
26. Upmalis DH, Lobo R, Bradley L, et al. Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: a multicenter double-blind randomized placebo-controlled study. Menopause. 2000;7:236-42.
27. Cheng G, Wilczek B, Warner M, Gustafsson JA. Isoflavone treatment for acute menopausal symptoms. Menopause. 2007;14:468-73.
28. Nahas EA, Nahas-Neto J, Orsatti FL, et al. Efficacy and safety of a soy isoflavone in postmenopausal women: a randomized double-blind, and placebo-controlled study. Maturitas. 2007;58:249-58.
29. Kaari C, Haidar MA, Soares JM, et al. Randomized clinical trial comparing conjugated equine estrogens and isoflavones in postmenopausal women: a pilot study. Maturitas. 2006;53:49-58.
30. American College of Obstetricians and Gynecologists. Use of botanicals for management of menopausal symptoms. ACOG Practice Bulletin. 2001;28:1-11.
31. Tice JA, Ettinger B, Ensrud K, et al. Phytoestrogen supplements for the treatment of hotflashes: the isoflavone clover extract (ICE) study. JAMA. 2003;290:207-14.
32. Knight DC, Howes JB, Eden JA. The effect of Promensil, an isoflavone extract, on menopausal symptoms. Climacteric. 1999;2:79-84.
33. Baber RJ, Templeman C, Morton T, et al. Randomized placebo controlled trial of an isoflavone supplement and menopausal symptoms in women. Climacteric. 1999;2:85-92.
34. Hidalgo LA, Chedraui PA, Morocho N, et al. The effect of red clover isoflavones on menopausal symptoms, lipids and vaginal cytology in menopausal women: a randomized, double blind, placebo-controlled study. Gynecol Endocrinol. 2005;21:257-64.
35. VandeWeijer P, Barentsen R. Isoflavones from red clover (Promensil) significantly reduce menopausal hot flush symptoms compared to placebo. Maturitas. 2002;42:187-93.
36. Jeri A. The use of an isoflavone supplement to relieve hot flushes. Female patient. 2002;27:47-9.
37. Red clover. Natural medicines comprehensive database [database online]. Stockton, CA: Therapeutic Research Center. Updated July 1, 2010.
38. Bodinet C, Freudenstein J. Influence of marketed herbal menopause preparations on MCF-7 cell proliferation. Menopause. 2004;11:281-9.
39. Burdette JE, Liu J, Chen SN, et al. Black cohosh acts as a mixed competitive ligand and partial agonist of serotonin receptor. J Agric Food Chem. 2003;51:5661-70.
40. Borelli F, Ernst E. Cimicifuga racemosa: a systematic review of this clinical efficacy. Eur J Clin Pharmacol. 2002;58:235-41.
41. Jacobsoen JS, Troxel AB, Evans J, et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol. 2001;19:2739-45.
42. Frei-Kleiner S, Schaffner W, Rahlfs VW, et al. Cimicifuga racemosa dried ethanolic extract in menopausal disorders: a double blind placebo-controlled clinical trial. Maturitas. 2005;51:397-404.
43. Newton KM, Reed SD, LaCroix AZ, et al. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy or placebo. Ann Intern Med. 2006;145:869-79.
44. Pockaj BA, Gallagher JG, Loprinzi CL, et al. Phase III double-blind, placebo-controlled, crossover trial of black cohosh in the management of hot flashes: NCCTG trial N01CC. J Clin Oncol. 2006;24:2836-41.
45. Pockaj BA, Loprinzi CL, Sloan JA, et al. Pilot evaluation of black cohosh for the treatment of hot flashes in women. Cancer Invest. 2004;22:515-21.
46. Vermes G, Banhidy F, Acs N. The effects of remifemin on subjective symptoms of menopause. Adv Ther. 2005;22:148-54.
47. Hernández Muñoz G, Pluchino S. Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer. Matruritas. 2003;44(suppl 1):S59-65.
48. Wuttke W, Seidlova-Wuttke D, Gorkow C. The cimicifuga preparation BNO 1005 vs. conjugated estrogens in double-blind placebo-controlled study: effects on menopause symptoms and bone markers. Maturitas. 2003;44(suppl 1):S67-77.
49. Nappi RE, Malavasi B, Brundu B, Facchinetti F. Efficacy of cimicifuga racemosa on climacteric complaints: a randomized study versus low-dose transdermal estradiol. Gynecol Endocrinol. 2005;20:30-5.
50. Oktem M, Eroglu D, Karahan HB, et al. Black cohosh and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized trial. Adv Ther. 2007;24:448-61.
51. Bai W, Zepelin HH, Wang S, et al. Effiacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: a randomized, double blind, parallel-controlled study versus tibolone. Maturitas. 2007;58:31-41.
52. Black cohosh. Natural medicines comprehensive database [database online]. Stockton, CA: Therapeutic Research Center. Updated July 1, 2010.
53. Teschke R. Black cohosh and suspected hepatotoxicity: inconsistencies, confounding variables, and prospective use of a diagnostic causality algorithm. Menopause. 2010;17:426-40.
54. Barton DL, Loprinzi CL, Quella SK, et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol. 1998;16:495-500.
55. Ziaei S, Kazemnejad A, Zareai M. The effect of vitamin E on hot flashes in menopausal women. Gynecol Obstet Invest. 2007;64:204-7.
56. Blatt MHG, Weisbader H, Kupperman HS. Vitamin E and climacteric syndrome. Arch Intern Med. 1953;91:792-6.
57. Miller ER, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high dosage vitamin E supplementations may increase all-cause mortality. Ann Intern Med. 2005;142:37-46.
58. Bjelakovic G, Nickolova N, Gluud LL, et al. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA. 2007;237:842-57.
59. North American Menopause Society. Section H: nonprescription therapies. In: Menopause practice: a clinician's guide. 3rd ed. Mayfield Heights, OH: North American Menopause Society; 2007:237-58.
60. Hirata JD, Swiersz LM, Zell B, et al. Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial. Fertil Steril. 1997;68:981-6.
61. Chenoy R, Hussain D, Tayob Y, et al. Effect of oral gamolenic acid from evening primrose oil on menopausal flushing. BMJ. 1994;308:501-3.
62. Wiklund IK, Mattsson LA, Lindgren R, Limoni C. Effects of standardized ginseng extract on quality of life and physiological parameters in symptomatic postmenopausal women: a double-blind, placebo-controlled trial. Int J Clin Pharmacol Res. 1999;19:89-99.
63. Warnecke G. Psychosomatic dysfunctions in the female climacteric: clinical effectiveness and tolerance of kava extract WS 1490. Fortschr Med. 1991;10:119-22.
64. Secreto G, Chiechi LM, Amadori A, et al. Soy isoflavones and melatonin for the relief of climacteric symptoms: a multicenter, double-blind, randomized study. Maturitas. 2004;47:11-20.
65. Komesaroff PA, Black CV, Sudhir K. Effects of wild yam extract on menopausal symptoms, lipids and sex hormones in healthy menopausal women. Climacteric. 2001;4:144-50.
66. Chung DJ, Kim HY, Park KH, et al. Black cohosh and St. John's wort (Gyno-Plus) for climacteric symptoms. Yonsei Med J. 2007;48:289-294.
67. Rotem C, Kaplan B. Phyto-Female Complex for the relief of hot flushes, night sweats and quality of sleep: randomized, controlled, double-blind pilot study. Gynecol Endocrinol. 2007;23:117-22.